News
Exactech Launches Gibralt® OCT Spinal System for Complex Cervical Thoracic Spine Procedures
Gainesville, Fla. – May 6, 2013 – Exactech, Inc. (Nasdaq: EXAC), which designs and manufactures bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, said that its Exactech Spine division has received FDA clearance of its new Gibralt® Occipital Spine System, which includes occipital plates and 360⁰ articulating rods.
Exactech Q1 Net Income up 17% to $3.8 Million. Diluted EPS $.29 vs. $.25. Worldwide Sales Up 1% to $59.3 Million. U.S. Sales Increased 6%.
GAINESVILLE, Fla. – April 23, 2013 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today sales of $59.3 million for the first quarter of 2013, a 1% increase over $58.6 million in the first quarter of 2012. Net income was $3.8 million, or $0.29 per diluted share, compared to $3.3 million, or $0.25 per diluted share, in the same quarter a year ago.
Exactech Schedules First Quarter 2013 Earnings Release and Conference Call
GAINESVILLE, Fla. – April 16, 2013 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will release its first quarter 2013 financial results on Tuesday, April 23, 2013. A copy of the earnings release will be available at http://www.hawkassociates.com
Exactech to Showcase Innovations in Joint Replacement During AAOS Annual Conference in Chicago
Gainesville, Fla. – March 18, 2013 – Exactech, Inc. (Nasdaq: EXAC), which designs and manufactures bone and joint restoration products for hip, knee, shoulder and spine procedures, announced today that Exactech Chief Executive Officer Bill Petty, MD, will discuss the company’s financial highlights at Canaccord Genuity’s Musculoskeletal Conference in Chicago on March 19, 2013.
Exactech 2012 Revenue Up 9% to $224.3M, Net Income Up 44% to $12.7M, EPS $0.96
GAINESVILLE, Fla. – February 26, 2013 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder and spine, announced today that revenue for 2012 increased 9% to $224.3 million from $205.4 million in 2011. Diluted earnings per share for the year was $0.96 based on net income of $12.7 million representing a 44% increase compared to net income of $8.8 million or $0.67 diluted EPS during 2011.
Exactech Announces Preliminary 2012 Sales of $224.8 Million and 4th Quarter 2012 Sales of $59.7 Million
GAINESVILLE, Fla. – January 22, 2013 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that it expects to report revenue for the fourth quarter of 2012 of $59.7 million, an increase of 13% compared to $53.1 million for the fourth quarter of 2011 which will result in full year unaudited revenues of $224.8 million, compared to $205.4 million for 2011, a 9% increase
Stay Connected